Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2017-06-20 Investor Presentation
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Galapagos’ R&D Update 2017: rapidly advancing our product candidates
Investor Presentation Classification · 98% confidence The document is titled 'Galapagos' R&D Update 2017' and details progress across multiple drug candidates (Filgotinib, Cystic Fibrosis combos, GLPG1690, GLPG1972). It announces specific clinical milestones, data readouts (e.g., DARWIN 3 interim readout, topline data for GLPG1690 in Q3 '17), and regulatory steps (opening US IND). It is a comprehensive update on research and development activities, often presented to investors. This content strongly aligns with an Investor Presentation (IP), which typically covers strategy, pipeline progress, and financial outlook in detail, often preceding or accompanying an earnings release or annual report. It is not a formal regulatory filing like a 10-K, nor is it just a short announcement of a report (RPA/RNS). It is a detailed presentation of operational and R&D progress.
2017-06-20 English
Galapagos’ R&D Update 2017: snelle ontwikkeling van onze kandidaatmedicijnen
Earnings Release Classification · 95% confidence The document is titled "Galapagos' R&D Update 2017: snelle ontwikkeling van onze kandidaatmedicijnen" and details progress across various drug candidates (Filgotinib, Cystic Fibrosis treatments, GLPG1690, GLPG1972). It explicitly states that the information is being announced during the company's 'jaarlijkse R&D Update' (Annual R&D Update) on June 20, 2017. This type of detailed pipeline and research progress update, often presented to investors and analysts, aligns best with an Investor Presentation (IP) or a comprehensive Management Discussion/Analysis (MDA) if it were part of a larger filing. However, given the context of a specific 'Update' event, and the detailed scientific/clinical data provided, it functions as a comprehensive investor briefing document. Since it is not a formal regulatory filing like a 10-K or IR, and it is more detailed than a simple Earnings Release (ER), 'Investor Presentation' (IP) is the most appropriate classification for this type of strategic update material, even if it was delivered via webcast/conference call. It is not an RPA because it is the substantive content itself, not just an announcement that content is available. It is not a CT because it is the prepared material, not the transcript of the Q&A session, although a Q&A session follows. H1 2017
2017-06-20 Dutch
Share Capital Increase - 20 June 2017_EN.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a 'share capital increase arising from warrant exercises,' detailing the issuance of new ordinary shares and the resulting change in total share capital and voting rights. This directly relates to changes in the company's capital structure and share count. Based on the definitions, 'Share Issue/Capital Change (Code: SHA)' is the most appropriate classification, as it covers announcements regarding new share issues or capital structure changes. It is not a general financing update (CAP) but a specific notification about the resulting share count.
2017-06-20 English
Share Capital Increase - 20 June 2017_NL.pdf
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces a capital increase resulting from the exercise of warrants by management and directors, leading to the issuance of new shares and an update to the total number of voting rights and share capital. This directly relates to changes in the company's capital structure and financing activities. The most fitting category is 'Capital/Financing Update' (CAP). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV). Since it details the issuance of new shares due to warrant exercise, it also touches upon share changes, but the primary focus is the capital raising event itself.
2017-06-20 Dutch
S-8 Filing
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the U.S. Securities and Exchange Commission. Form S-8 is used for registering securities to be offered to employees under employee benefit plans, such as stock option or warrant plans. The document includes detailed information about the securities to be registered, indemnification of directors and officers, and undertakings related to the registration. It is not a financial report, earnings release, or management discussion, nor is it an announcement of voting results or a proxy statement. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it contains substantive content, not just a brief announcement or certification, supporting this classification with high confidence.
2017-05-22 English
Galapagos creates new warrant plan
Share Issue/Capital Change Classification · 99% confidence The document is a press release from Galapagos NV dated May 17, 2017, announcing the creation of a new warrant plan for employees, directors, and consultants. It details the number of warrants, the exercise price, the term, and the impact on the total number of shares and voting rights. This type of announcement, dealing with the issuance of new securities (warrants) that affect the capital structure and potential share count, aligns best with the 'Capital/Financing Update' category. While it involves shares, it is specifically about creating options (warrants) rather than a direct share issue or repurchase (SHA/POS). It is not a full financial report (10-K/IR), an earnings release (ER), or a management discussion (MDA). Therefore, CAP (Capital/Financing Update) is the most appropriate classification.
2017-05-18 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.